Past Users: Length of use, reason for stopping, perceived benefits and disadvantages, likelihood to use again, and claimed impact on daily health and wellbeing
Modern GLP-1 receptor agonists have demonstrated average weight loss of 15-20% of body weight with sustained treatment, representing a breakthrough in obesity pharmacotherapy that approaches the effectiveness of bariatric surgery
States like Colorado and the District of Columbia sit at the lower end
* Disclaimer - Based on a comparison of studies measuring weight loss with similar BMI measurements over a 8 week period for active Noom Med patients prescribed a GLP-1 medication and active Noom Healthy Weight customers not taking medication
Drink it alongside, not instead of, water
Ozempic does not have a dedicated self-pay pricing program